Factor VIII concentrate-responsive thrombocytopenia, hemolytic anemia, and nephropathy. Evidence that factor VIII:von Willebrand factor is involved in its pathogenesis

Am J Pediatr Hematol Oncol. 1986 Winter;8(4):324-8. doi: 10.1097/00043426-198624000-00010.

Abstract

A 4-year-old Japanese girl had a congenital disorder that was characterized by recurrent thrombocytopenia, hemolytic anemia, hematuria, and proteinuria, which were repeatedly improved by the infusion of factor VIII concentrate. She developed the similar symptoms within 1 h after 1-desamino-8-D-arginine vasopressin (DDAVP) administration. Coagulation studies 30 and 60 min after DDAVP infusion showed a disappearance of large factor VIII:von Willebrand factor (VIII:vWF) multimers, which was the same abnormality that was observed at acute episodes. There were no significant changes in the plasma levels of 6-keto-prostaglandin F1 alpha and thromboxane B2 before and after DDAVP infusion. These results provide further support that VIII:vWF is directly involved in the pathogenesis of this congenital disorder.

Publication types

  • Case Reports

MeSH terms

  • Anemia, Hemolytic / therapy*
  • Child, Preschool
  • Deamino Arginine Vasopressin / pharmacology
  • Factor VIII / metabolism
  • Factor VIII / therapeutic use*
  • Female
  • Humans
  • Kidney Diseases / therapy*
  • Macromolecular Substances
  • Recurrence
  • Thrombocytopenia / therapy*
  • von Willebrand Factor / metabolism

Substances

  • Macromolecular Substances
  • von Willebrand Factor
  • Factor VIII
  • Deamino Arginine Vasopressin